Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohort

Key Takeaways

• A new analysis of real-world US data show higher baseline and post-diagnosis rates of autoimmune, infectious, and hearing-related events in patients with vitiligo.
• Incidence and prevalence of vitiligo were numerically higher in Asian and Hispanic populations.
• Malignancy findings were inconsistent with prior literature and should be interpreted cautiously due to EHR limitations.

New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls.

Investigators analyzed Optum Market Clarity EHR data from 2016 to 2023 (including 15,047 patients with vitiligo and 75,231 age-, sex-, and race-matched controls). Median age was 51 years, and 56.3% were female.

Patients with vitiligo had higher baseline rates of autoimmune and inflammatory diseases—including autoimmune thyroiditis, psoriasis, and alopecia areata—as well as infections, malignancies, hypothyroidism, allergic rhinitis, and hearing loss.

During follow-up, incidence rates (IRs) of autoimmune conditions remained elevated. For example, alopecia areata (4.52 vs 0.34 per 1000 patient-years) and autoimmune thyroiditis (5.90 vs 1.46) were more frequent in the vitiligo cohort. Infection-related events, including herpes simplex and herpes zoster, were also modestly higher. Hearing-related outcomes, such as sensorineural hearing loss (8.75 vs 5.13), were increased as well.

Malignancy rates—including nonmelanoma skin cancer—were numerically higher, though the authors note these findings contrast with prior studies and may reflect coding limitations. Psychiatric and cardiovascular event rates were lower in the vitiligo cohort, differing from some earlier literature.

Epidemiologic analyses showed higher prevalence and incidence among Asian and Hispanic populations compared with other groups.

“This retrospective, observational cohort study…revealed that certain autoimmune and inflammatory conditions, specific infections, select malignancies, hypothyroidism, allergic rhinitis, and hearing loss were more common…[and] higher IRs of several comorbidities were observed in the vitiligo cohort,” the authors wrote.

These findings provide context for baseline risk in vitiligo populations, particularly as JAK inhibitors and other systemic therapies are increasingly evaluated.

Source: Cook K, Elbuluk NM, Adiri R, et al. J Dermatol. 2026;0:1-16. Doi:10.1111/1346-8138.70256.